2m 2m 2m 2m 2m 2m 2m
TRAVERE THERAPET (TVTX)
NASDAQ
$54.76-$1.19 (-2.12%)
Price as of Jun 23, 2026 7:58 PM EDT- $5.1BMarket Cap
- 267.13%1-Year Change
- BiotechnologyIndustry
TRAVERE THERAPET (TVTX)
$54.76-$1.19 (-2.12%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 410.5M +76.03% | 233.2M +60.55% | 145.2M -31.50% | 212.0M -6.80% | |
Cost of Revenue | 10.3M +33.51% | 7.7M -32.37% | 11.4M +50.82% | 7.6M +11.91% | |
Gross Profit | 400.1M +77.49% | 225.4M +68.50% | 133.8M -34.55% | 204.4M -7.38% | |
Sales and Marketing Expense | 337.2M +27.67% | 264.1M -0.54% | 265.5M +20.59% | 220.2M +46.92% | |
Research and Development Expense | -206.0M -5.28% | -217.5M -11.22% | -245.0M +3.91% | -235.8M +12.10% | |
Depreciation and Amortization Expense | 60.7M +39.46% | 43.6M +13.04% | 38.5M +16.48% | 33.1M +24.28% | |
Total Operating Expenses | 553.6M -0.62% | 557.0M +4.43% | 533.4M +11.45% | 478.6M +22.95% | |
Operating Profit | -62.8M -80.60% | -323.8M -16.57% | -388.1M +45.61% | -266.6M +64.79% | |
Interest Income | 12.7M -28.60% | 17.8M -18.15% | 21.8M +246.85% | 6.3M +214.90% | |
Interest Expense | -10.0M -5.56% | -10.6M -6.80% | -11.3M +0.52% | -11.3M -44.02% | |
Interest Income and Expense and Net | 2.7M -62.16% | 7.3M -30.48% | 10.4M +308.72% | -5.0M -72.45% | |
Total Nonoperating Income and Expense | 13.6M +308.53% | 3.3M -72.42% | 12.0M +203.66% | -11.6M -35.24% | |
Income before Taxes | -49.3M -84.63% | -320.5M -14.78% | -376.1M +35.21% | -278.2M +54.81% | |
Income Taxes | 988,000 +723.33% | 120,000 -46.19% | 223,000 -28.75% | 313,000 -23.47% | |
Extraordinary Items | 0 -100.00% | 1.2M N/A | N/A N/A | N/A N/A | |
Net Income | -25.5M -92.06% | -321.5M +188.64% | -111.4M -60.00% | -278.5M +54.63% | |
Net Income from Continuing Operations Applicable to Common | -50.3M -84.32% | -320.6M -14.80% | -376.3M +35.29% | -278.2M +54.81% | |
Basic EPS and Net Income | -0.29 -92.89% | -4.08 +172.00% | -1.50 -65.68% | -4.37 +45.18% | |
Diluted EPS and Net Income | -0.29 -92.89% | -4.08 +172.00% | -1.50 -65.68% | -4.37 +45.18% | |
Basic Weighted Average Shares | 89.2M +13.09% | 78.9M +6.22% | 74.3M +16.48% | 63.8M +6.56% | |
Diluted Weighted Average Shares | 89.2M +13.09% | 78.9M +6.22% | 74.3M +16.48% | 63.8M +6.56% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 93.0M +58.94% | 58.5M +0.62% | 58.2M -5.69% | 61.7M -62.78% | |
Short-Term Investments | 63.0M -74.67% | 248.6M 0.00% | 248.6M -12.92% | 285.5M +8.90% | |
Cash and Cash Equivalents and Short-Term Investments | 156.0M -49.21% | 307.2M +0.12% | 306.8M -11.64% | 347.2M -18.86% | |
Total Current Assets | 437.6M +5.01% | 416.7M -32.44% | 616.8M +26.79% | 486.4M -16.54% | |
Accumulated Depreciation | 10.1M +15.34% | 8.8M +17.63% | 7.4M +43.27% | 5.2M +70.44% | |
Property and Plant and Equipment and Net | 4.0M -24.63% | 5.3M -28.65% | 7.5M -17.35% | 9.0M -18.52% | |
Total Long-Term Assets | 8.9M -51.11% | 18.2M +70.36% | 10.7M -3.62% | 11.1M -0.07% | |
Total Assets | 605.2M +1.86% | 594.1M -24.69% | 788.9M +17.30% | 672.6M -13.40% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | 300,000 N/A | |
Total Short-Term Debt | 0 -100.00% | 68.7M N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 159.9M -20.35% | 200.8M +12.84% | 177.9M +25.14% | 142.2M +14.57% | |
Total Long-Term Debt | 311.7M +0.46% | 310.3M -17.75% | 377.3M +0.46% | 375.5M +65.74% | |
Total Long-Term Liabilities | 7.6M +11.85% | 6.8M -19.91% | 8.5M -9.59% | 9.4M -23.55% | |
Total Liabilities | 490.4M -8.35% | 535.0M -9.02% | 588.1M -6.61% | 629.7M +32.71% | |
Retained Earnings | -1.5B +1.77% | -1.4B +28.57% | -1.1B +10.98% | -1.0B +32.41% | |
Total Stockholders Equity | 114.8M +94.37% | 59.1M -70.58% | 200.8M +368.62% | 42.9M -85.82% | |
Total Shares Outstanding | 90.9M +3.97% | 87.5M +16.04% | 75.4M +17.23% | 64.3M +2.88% | |
Cash Flow | |||||
Cash from Operating Activities | 37.8M +115.91% | -237.5M -15.19% | -280.0M +50.31% | -186.3M +1,159.40% | |
Capital Expenditures | N/A N/A | N/A N/A | 668,000 +249.74% | 191,000 -96.26% | |
Cash from Investing Activities | 27.9M -71.92% | 99.3M +78.08% | 55.8M +271.34% | -32.6M -76.35% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -33.5M -124.00% | 139.4M -36.26% | 218.8M +86.06% | 117.6M -49.25% | |
Financials Ratio | |||||
Gross Margin | 97.48% +0.83% | 96.68% +4.95% | 92.12% -4.46% | 96.42% -0.62% | |
Operating Margin | -15.31% -88.98% | -138.88% -48.03% | -267.24% +112.56% | -125.73% +76.81% | |
Return on Assets | -4.26% -90.84% | -46.50% +205.02% | -15.24% -60.33% | -38.43% +47.68% | |
Return on Equity | -29.38% -88.13% | -247.45% +170.62% | -91.44% -43.37% | -161.46% +130.10% | |
Revenue Growth | 76.03% +25.57% | 60.55% +292.23% | -31.50% +363.11% | -6.80% -146.24% | |
Current Ratio | 2.74 +31.83% | 2.08 -40.13% | 3.47 +1.32% | 3.42 -27.15% | |
Cash Ratio | 0.58 +99.52% | 0.29 -10.83% | 0.33 -24.64% | 0.43 -67.52% | |
Debt-to-Equity Ratio | 2.71 -57.68% | 6.42 N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.52 -19.25% | 0.64 N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow